ArticleFrontiers in microbiology2020
Identification of a Type IV-A CRISPR-Cas System Located Exclusively on
Article in Frontiers in microbiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 55 citations in OpenAlex.
- CRISPR-Cas is beneficial in plasmid competition, but limited by competitor toxin-antitoxin activity when horizontally transferred.PLoS biology · 2026Article
- Characterization and engineering of a type IV-A3 CRISPR-Cas system for genome editing in Escherichia coli.Nucleic acids research · 2025Article
- Type I-Fv and engineered type IV-A1 CRISPR-Cas effectors facilitate genome reduction in Escherichia coli.Nucleic acids research · 2025Article
- The extended mobility of plasmids.Nucleic acids research · 2025Review
- CRISPR-Cas Dynamics in Carbapenem-Resistant and Carbapenem-SusceptiblePathogens (Basel, Switzerland) · 2025Article
- Intricate interplay of CRISPR-Cas systems, anti-CRISPR proteins, and antimicrobial resistance genes in a globally successful multi-drug resistant Klebsiella pneumoniae clone.Genome medicine · 2025Article
- Developing a Versatile Arsenal: Novel Antimicrobials as Offensive Tools Against Pathogenic Bacteria.Microorganisms · 2025Review
- Determining the biochemical function of type IV CRISPR ribonucleoprotein complexes and accessory proteins.Methods in enzymology · 2025Article
- CRISPR in mobile genetic elements: counter-defense, inter-element competition and RNA-guided transposition.BMC biology · 2024Review
- Mobilizable plasmids drive the spread of antimicrobial resistance genes and virulence genes in Klebsiella pneumoniae.Genome medicine · 2023Article
- Characterization and diversity of CRISPR/Cas systems in Klebsiella oxytoca.Molecular genetics and genomics : MGG · 2023Article
- CasDinG is a 5'-3' dsDNA and RNA/DNA helicase with three accessory domains essential for type IV CRISPR immunity.Nucleic acids research · 2023Article
- Genomic Insights into CRISPR-Harboring Plasmids in the Klebsiella Genus: Distribution, Backbone Structures, Antibiotic Resistance, and Virulence Determinant Profiles.Antimicrobial agents and chemotherapy · 2023Article
- What makes a megaplasmid?Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2022Article
- Genomic evolution of the globally disseminated multidrug-resistantMicrobial genomics · 2022Article
- Hybrid Plasmids Encoding Antimicrobial Resistance and Virulence Traits Among HypervirulentFrontiers in cellular and infection microbiology · 2022Article
- Engineered CRISPR-Cas systems for the detection and control of antibiotic-resistant infections.Journal of nanobiotechnology · 2021Review
- Evolutionary genomics and biosynthetic potential of novel environmental Actinobacteria.Applied microbiology and biotechnology · 2021Article
- AMicrobial genomics · 2021Article
- Evolution of Type IV CRISPR-Cas Systems: Insights from CRISPR Loci in Integrative Conjugative Elements ofThe CRISPR journal · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) are diverse immune systems found in many prokaryotic genomes that target invading foreign DNA such as bacteriophages and plasmids. There are multiple types of CRISPR with arguably the most enigmatic being Type IV. During an investigation of CRISPR carriage in clinical, multi-drug resistant,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.